Oncology
Please note that you will be redirected to one of our sister websites, ManagingMyeloma.com or PracticalOncologist.com, where these courses are maintained. You will need to log in if you are already a member of the websites or take a minute to register for complimentary membership.
![]() | Novel Approaches for the Management of Elderly and Infirm Multiple Myeloma Patients Antonio Palumbo, MD and Sandra E. Kurtin, RN, MS, AOCN®, ANP-C | |
| Release Date: March 29, 2013 Expiration Date: March 29, 2014 | ||
| World-leading myeloma expert, Dr. Antonio Palumbo, describes strategies to tailoring therapy for specific elderly multiple myeloma patient needs, including recently proposed algorithms to assist in adjusting regimens as needed. Sandra Kurtin, nurse practitioner and assistant professor of clinical medicine and nursing at the University of Arizona further discusses special practice considerations including age, performance status, previous medical history, and tailoring supportive care based on patient specific risk factors for treatment associated side effects. Provided by MediCom Worldwide, Inc. This activity is supported by educational grants from Millennium: The Takeda Oncology Company and Celgene Corporation. | ||
| Begin | ||
| Advances in Consolidation, Stem Cell Collection, and Transplantation Sergio Giralt, MD, and Beth Faiman, PhDc, RN, MSN, APRN-BC, AOCN® | ||
| Release Date: March 15, 2013 Expiration Date: March 15, 2014 | ||
| Sergio Giralt, MD, and Beth Faiman, PhDc, RN, MSN, APRN-BC, AOCN®, navigate the management decision process for transplant-eligible patients, including tailoring treatment planning, establishing treatment goals, primary therapy choices, and addressing patient concerns as to whether autologous stem cell transplant is a necessity. Provided by MediCom Worldwide, Inc. This activity is supported by educational grants from Millennium: The Takeda Oncology Company and Celgene Corporation. | ||
| Begin | ||
![]() | The Multidisciplinary Team Approach: Managing the Newly Diagnosed Patient Sergio A. Giralt, MD, R. Donald Harvey III, PharmD, FCCP, BCPS, BCOP, and Beth Faiman, RN, MSN, APRN-BC, AOCN® | |
| Release Date: July 12, 2012 Expiration Date: July 12, 2013 | ||
| Join renowned multiple myeloma expert Sergio A. Giralt, MD, along with his colleagues R. Donald Harvey III, PharmD, FCCP, BCPS, BCOP, and Beth Faiman, RN, MSN, APRN-BC, AOCN® as they discuss the case of a newly diagnosed, transplant-eligible patient. This case will focus on considerations for management planning based on the patient’s medical history and comorbidities within the multidisciplinary setting. Provided by MediCom Worldwide, Inc. This activity is supported by an educational grant from Millennium: The Takeda Oncology Company | ||
| Begin | ||
![]() | New Paradigms in Chronic Myelogenous Leukemia Eric J. Feldman, MD; Neil Shah, MD, PhD | |
| Release Date: February 20, 2013 Expiration Date: February 20, 2014 | ||
| Join Dr. Feldman and Dr. Shah for a joint conversation regarding specific management considerations in a series of real-world CML cases. In a supplemental resource (not required for credit), Dr. Feldman leads a discussion regarding treatment and management options for chronic myelogenous leukemia (CML), including trial outcomes for emerging therapeutic approaches. Provided by MediCom Worldwide, Inc. This activity is supported by an educational grant from Bristol-Myers Squibb. | ||
| Begin | ||
![]() | Treatment and Maintenance Therapy for Prolonging Remission and Delaying Relapse in Follicular Lymphoma Christopher Flowers, MD; Stephen Schuster, MD | |
| Release Date: January 22, 2013 Expiration Date: January 22, 2014 | ||
| Dr. Flowers leads a discussion regarding treatment and management options for follicular lymphoma, including trial outcomes for emerging therapeutic approaches, followed by a joint conversation with Dr. Schuster regarding specific management considerations in a series of real-world follicular lymphoma cases. Provided by MediCom Worldwide, Inc. This activity is supported by an educational grant from Genentech, Inc. | ||
| Begin | ||




